| Literature DB >> 28943728 |
Sathish Sankar1, Mageshbabu Ramamurthy1, Balaji Nandagopal1, Gopalan Sridharan1.
Abstract
Several genotypes of the hantavirus cause hemorrhagic fever with renal syndrome (HFRS) and is an important public health problem worldwide. There is now growing interest to develop subunit vaccines especially focused to elicit cytotoxic T lymphocyte responses which are important against viral infection. We identified candidate T-cell epitopes that bind to Class I HLA supertypes towards identifying potential subunit vaccine entity. These epitopes are conserved in all 5 hantavirus genotypes of HFRS (Hantaan, Dobrava- Belgrade, Seoul, Gou virus and Amur). The epitopes identified from S and M segment genomes were analyzed for human proteasome cleavage, transporter associated antigen processing (TAP) efficiency and antigenicity using bioinformatic approaches. The epitope MRNTIMASK which had the two characteristics of high proteasomal cleavage score and TAP score, also had high antigenicity score. Our results indicate that this epitope from the nucleocapsid protein may be considered the most favorable moiety for the development of subunit peptide vaccine.Entities:
Keywords: HFRS; Short peptide; epitope design; hantaviruses
Year: 2017 PMID: 28943728 PMCID: PMC5602290 DOI: 10.6026/97320630013231
Source DB: PubMed Journal: Bioinformation ISSN: 0973-2063
Figure 1Flowchart indicating the study design
List of epitopes from S and M segment that are present in all five genotypes and their prediction scores for suitability as potential peptide vaccine.
| Epitopes | Peptide position | HLA supertypes | Proteasomal cleavage | TAP score | Vaxijen score |
| S segment | |||||
| YLTSFVVPI | 125 | HLA-A*02:01 | X | 4.947 (intermediate) | -0.1023 (non-antigen) |
| SYLRRTQSM | 364 | HLA-A*24:02; HLA-B*08:01; | X | 4.015 (intermediate) | 0.6938 (antigen) |
| MRNTIMASK | 338 | HLA-B*27:05 | 0.5044 | 6.211 (high) | 0.7426 (antigen) |
| KSSFYQSYL | 358 | HLA-B*58:01 | X | 6.344 (high) | -0.1575 (non-antigen) |
| M segment | |||||
| HTDLELDFS | 668 | HLA-A*01:01 | X | -0.227 (low) | 2.1801 (antigen) |
| YTITSLFSL | 452 | HLA-A*02:01; HLA-A*26:01; HLA-B*39:01 | X | 3.954 (intermediate) | 0.3892 (non-antigen) |
| EAFSEGGIF | 388 | HLA-A*26:01 | X | 8.597 (high) | 0.1765 (non-antigen) |
| YRTLNLFRY | 613 | HLA-B*27:05 | X | 3.841 (intermediate) | -0.1871 (non-antigen) |
| WGSGVGFTL | 981 | HLA-B*39:01 | 0.5006 | 0.581(low) | 0.6654 (antigen) |
| LCVPGFHGW | 472 | HLA-B*58:01 | X | 4.795 (intermediate) | -0.1392 (non-antigen) |
| X- indicates cleavage within the peptide | |||||